Nerve growth factor, brain-derived neurotrophic factor, and the chronobiology of mood: a new insight into the “neurotrophic hypothesis”

Abstract: The light information pathways and their relationship with the body rhythms have generated a new insight into the neurobiology and the neurobehavioral sciences, as well as into the clinical approaches to human diseases associated with disruption of circadian cycles. Light-based strategies and/or drugs acting on the circadian rhythms have widely been used in psychiatric patients characterized by mood-related disorders, but the timing and dosage use of the various treatments, although based on international guidelines, are mainly dependent on the psychiatric experiences. Further, many efforts have been made to identify biomarkers able to disclose the circadian-related aspect of diseases, and therefore serve as diagnostic, prognostic, and therapeutic tools in clinic to assess the different mood-related symptoms, including pain, fatigue, sleep disturbance, loss of interest or pleasure, appetite, psychomotor changes, and cognitive impairments. Among the endogenous factors suggested to be involved in mood regulation, the neurotrophins, nerve growth factor, and brain-derived neurotrophic factor show anatomical and functional link with the circadian system and mediate some of light-induced effects in brain. In addition, in humans, both nerve growth factor and brain-derived neurotrophic factor have showed a daily rhythm, which correlate with the morningness–eveningness dimensions, and are influenced by light, suggesting their potential role as biomarkers for chronotypes and/or chronotherapy. The evidences of the relationship between the diverse mood-related disorders, with a specific focus on depression, and neurotrophins are reviewed and discussed herein in terms of their circadian significance, and potential translation into clinical practice.

Keywords: retinal ganglionic cells, mesocorticolimbic circuits, chronotherapy, ocular eye drops administration, neurotrophins

Neuroanatomical correlates of time, light, and mood
In humans, circadian (from the Latin word “circa diem”, meaning “about a day”) variations characterize multiple physiological and psychological functions, including core body temperature, endocrine and autonomic functions, sleep, mood, alertness, and cognitive performance (Figure 1).1,2 Sleep and wakefulness are the most obvious manifestations of the mammalian circadian system: during the day, light supports all the activities, while during the night, sleep is crucial for restoring the body and mind (cellular repair and mental recovery).2 The coordinator center of this system is the suprachiasmatic nucleus (SCN) located in the ventral hypothalamus (HYP) which receives direct projections from the retina and...
represents the master clock. All SCN neurons are coupled by autocrine/paracrine signals and by synaptic signals, and oscillate in coordinate manner to regulate the peripheral oscillators directly through the sympathetic and parasympathetic pathways, and indirectly by hormones, cytokines, and growth factors secretion.\(^3,4\) Conversely, signals arising from the periphery reach the brain and drive feedback information from the entire body in order to adapt the SCN activity, and generate a coherent functional network to regulate behaviors and physiology.

Important features of the SCN clock are its resilience to photic cues and the shifting phase during the dark phase, which guarantee the adaptation to geophysical time or environmental changes without generating a constant modification during the light phase. This is possible because although light is the most potent entraining cue, not all the light signals from the retina are capable of phase entrainment. Indeed, only a restricted number of retinal ganglion cells (RGCs), the intrinsically photosensitive retinal ganglion cells (ipRGCs) in the inner retina layer, contribute to regulate the circadian system.\(^5,6\) These cells express the light receptor melanopsin also in the absence of any other retinal input, and regenerate their chromophore without involving other cells.\(^7,8\) They constitute \(\sim 4\%–5\%\) of all RGCs, projecting to image-forming brain areas (M2-4-5 ipRGC types), also serving as a relay station for the rods and cones, and nonimage-forming (NIF) brain areas (M1 ipRGC type). Further, ipRGCs are most sensitive to short-wavelength (\(\sim 480\) nm) blue light, remain functional in the absence of rods and cones, and are resistant to injury.\(^8\) These properties guarantee that even in blindness or severe ocular pathological conditions, the ipRGCs-mediated effects do not require the fine spatial acuity necessary for image formation.\(^9\)

The NIF effects of light include heart rate and pupil diameter, the entrainment of circadian rhythms, and modulation of locomotor activity, as well as high-level cognitive and emotional processes.\(^10\)
Retrograde tracing experiments in animals and neuroimaging analysis in humans helped to identify their neuronal correlates, confirming that ipRGCs project directly to the SCN through the retinohypothalamic tract, but also show a widespread brain projection pattern from and to the SCN, which includes other hypothalamic nuclei, thalamic, striatal, brainstem, and limbic structures (Figure 2).7,11,12 Direct projections of ipRGCs to the amygdala (AMY) have been described in rodents, and a retina–AMY functional pathway, passing through the superior colliculus and thalamus, has also been found in humans.13 More, the AMY, the hippocampus (HIP), and the HYP are secondarily influenced by the NIF system by the locus coeruleus, which also receives projections from the SCN.13,14 These brain areas, which represent the neural circuits for the emotional and nonvisual cognitive information processing, and also for the circadian regulation of arousal, are selectively and wavelength dependently activated by acute light exposure, showing an increase in activity following blue light.10,15

Speculatively, light inputs to SCN also involve the dopaminergic mesocorticolimbic pathway, also called the reward circuit, which is also indicated as the common neuroanatomical and functional correlate of pain and depression.16 The core of the brain reward/aversion system is the ventral tegmental area and its projections to the nucleus accumbens (NAc), which sends the information to the subcortical limbic areas, like the AMY, the HIP, and the HYP, and then to the prefrontal cortex and the anterior cingulate cortex for processing.17 Brain endogenous opioids and dopamine (DA) pathways mainly regulate the activity of NAc neurons and the release of DA contributing to shape the behavioral response to rewarding or aversive stimuli.18

The diurnal variation of DA transmission in the mesocorticolimbic structures is dependent on the SCN and clock genes expression, thus supporting a functional correlation between the anatomical substrates for mood and mood-related symptoms, reward, and light stimuli.19,20 An integrated view of the anatomical network of NIF, mood, and reward signals is reported in Figure 2.

**Figure 2** Circadian, reward, and depression integrated network.

**Notes:** The major brain structures and pathways involved in light/timing signals (yellow), reward (blue), and depression (red) are shown. The SCN, the PIN, and the HB receive directly projections from the RGCs, but their activities are also modulated by the reward system via the VTA and the NAc. The circadian rhythm and functions of the hypothalamic nuclei, including awakening, alert, arousal, and feeding, are regulated by light signals through the SCN and by the reward system through the VTA/NAc network. In addition, ipRGCs project to the AMY, HB, and thalamus and PVN, thus influencing directly depression and anxiety. The complex network between the cortex, the forebrain, and the brainstem structures involved in mood, pain, timing, and reward contributes to integrate the internal and external signals into a mental/body rhythm, which characterizes an individual and identifies his specific physiological or pathological condition.

**Abbreviations:** ACC, anterior cingulate cortex; AMY, amygdala; BG, basal ganglia; DMHN, dorsomedial hypothalamic nuclei; HB, habenular nucleus; HIP, hippocampus; HYP, hypothalamus; ipRGCs, intrinsically photosensitive retinal ganglion cells; LH, lateral hypothalamus; NAc, nucleus accumbens; NTS, nucleus of the solitary tract; OC, optic chiasm; PAG, periaqueductal gray; PB, parabrachial nucleus; PFC, prefrontal cortex; PIN, pineal gland; PVN, paraventricular nucleus; RGCs, retinal ganglion cells; S1 and S2, somatosensory cortex; SCN, suprachiasmatic nucleus; SO, supraoptic nucleus; VLPO, ventrolateral preoptic nucleus; VTA, ventral tegmental area.
Brief NGF and BDNF neurobiology

The nerve growth factor (NGF) was discovered in the 1940s by the Nobel Price winners Rita Levi-Montalcini and Stanley Cohen, and it represents the first factor showing survival and differentiative effects on neuronal cells.21 Nowadays, NGF is known to be a member of a group of molecules sharing structural and functional activities, including the brain-derived neurotrophic factor (BDNF), and that are collectively named neurotrophins (NTs).22 Both NGF and BDNF are involved in the regulation of central nervous system development, and extend their survival, protective, and regenerative action on immature and mature neuronal cells during the entire life span, and even in pathological conditions.22

In mammalian brain, these two NTs and their receptors are distributed in all the forebrain areas. Concerning NT mRNAs, they were originally localized in the HIP and cortex, and lately in the striatum, the HYP, the brainstem, and pituitary. This demonstrated the synthesis of NTs in the brain, further suggesting how their local production might serve, beyond other things, to regulate the activities of interneurons, and/or the release of other factors/hormones via autocrine/paracrine mechanism (as reviewed by Sofroniew et al,22 Aloe et al,21 and Cirulli et al).24

Specific tyrosine kinase receptors, the TrkA and TrkB, mediate, respectively, most of the NGF and BDNF actions on their targets, but all the NTs also bind to a membrane glycoprotein p75 receptor (p75NTR), which can activate Trk-convergent or Trk-divergent pathways.22 Indeed, NTs binding to Trks alone or Trk/p75NTR conjointly trigger a complex network of intracellular signaling cascades, including induction of transcription factors (eg, c-fos), different classes of serine/threonine-selective protein kinases (eg, mitogen-activated protein [MAP] kinases), as well as intracellular tyrosine kinases, which result in survival and trophic effects.

Different intracellular signals can be mediated by p75NTR, which can activate survival through the nuclear factor-κB pathway, and antagonizes the actions of TrkA through the JUN N-terminal kinase and RHOA pathways. Moreover, it has been found that the precursor NGF and BDNF forms also exert biological activity, and chiefly, activate apoptotic signals in neurons by binding the p75NTR/sortilin complex.12,26

In line with this, the increased levels of proNTs associated with an unbalance of Trks/p75NTR are considered as part of a pathological cycle, which induces neuronal degeneration and results in impairment of brain and cognitive functions.27,28

Besides their action as survival factors, NGF and BDNF affect neurotransmitter synthesis and release influencing the activity-dependent synaptic plasticity, but also take part in the reorganization of the neuronal network induced by memory and stress, as well as in depression and following drug administration.29,30

The ability of NTs to stimulate survival of neuronal precursors and neurogenesis and modulate gliogenesis further contributes to support the NGF and BDNF involvement in the regulation of new born cells and connections generated by experiences and adaptation, and in the repair and connectivity rearrangement in pathological conditions.31

It is relevant to note that NGF and BDNF are synthesized in an activity-dependent manner and released upon neuron depolarization, and that they retrogradely and anterogradely act on presynaptic and postsynaptic neurons, respectively, but also exert autocrine and paracrine influence on the surrounding cells.29 Further, it has been observed that NGF is able to stimulate BDNF synthesis and/or release in vivo and to induce BDNF and NT3, another NT, release in vitro as a consequence of TrkA activation.32,33

On the contrary, BDNF-induced release of NT3 in PC12 cells is mediated by p75NTR activation but not by Trks, indicating that the changes in one NT expression might affect the synthesis of the other NTs, and that NTs release is dependent on the relative expression of Trk/p75NTR.34 In addition, the NTs-induced enhancement of their own synthesis occur in autocrine or paracrine manner implying a potential feedback mechanism relevant to synaptic plasticity and activity-dependent functions such as memory formation, learning, and adaptation to environmental change.

To strengthen this notion, the modification of NTs and NT receptors distribution in the brain, as well as changes in NGF or BDNF concentration in serum, is strictly associated with cognitive and emotional performance in experimental animals and humans, and with antidepressant (AD) and/or physical therapies supporting the concept of the “neurotrophic hypothesis” of mood-related disorders.

Furthermore, in the past years, the emerging contribution of visual system in the regulation of mood and cognition has offered the possibility to prospect a more integrated view of the NTs in affective neuroscience, and in the clinical approach to mood-related disorders, which includes the anatomical and functional interplay between the sensitivity and body response to light and the NTs anatomical and functional pathways.

NGF and BDNF in the retina–brain pathways

A large amount of investigations demonstrated the role played by NTs in the development and functional maintenance of
the visual system. Both NGF and BDNF and their receptors are expressed in the retina, optic nerve, the visual cortex, and the geniculate nucleus, where they regulate the proliferation, neurite outgrowth, and survival of cells. RGCs depend on the retrograde transport of NTs produced by the central targets, although both NGF and BDNF also exert paracrine and autocrine actions in the retina and the retinal recipient areas. Both exogenous and endogenous NTs can be anterogradely transported and therefore influence the survival of postsynaptic neurons and the development of synapses. Peculiarly, in RGCs, the NTs are not rapidly degraded after internalization, but they are differently sorted by a mechanism regulated by the Trks, so that NGF is mainly targeted to lysosomes, while BDNF is recycled to the surface membrane. NT receptors are also rapidly recycled to the cell surface, implying a regulation of receptor densities, and thus having a significant impact on the signals of survival or differentiation. The anterograde transport and the mechanism of NTs release at the postsynaptic levels also influence NTs produced in the retina, and in turn, the same retina/optic nerve pathways.

In this context, it is relevant that NGF and BDNF are synthesized in the SCN, and changes in circadian rhythmicity are observed when they are injected into the SCN or intracerebroventricularly, suggesting to be implicated in the regulation of the circadian clock.

Historically, the anatomical evidence that demonstrated a dense expression of p75NGFR in the SCN was thought to explain the observed NGF, and subsequently, BDNF effects. Actually, the functional relevance of p75NGFR in the SCN is controversial, since the p75NTR in this nucleus is localized on the axon terminals of RGC and basal forebrain neurons and does not identify vasoactive intestinal polypeptide (VIP) neurons as initially suggested by Kiss et al. Null mutation of p75 gene in mice does not alter circadian rhythms of behaviors in constant dark but decreases phase shifts induced by brief pulses of light, indicating that the lack of p75NTR might be compensated by other mechanisms.

Indeed, studies using the lesions of cholinergic projections to the SCN originating in the basal forebrain, and particularly in the nucleus basalis of Meynert and septum – the preferential NTs-responding neurons in the brain – demonstrated a role of p75NGF-cholinergic neurons in the regulation of SCN functions. However, these studies also show that residual p75-immunoreactive terminals from the retina – which might be less accessible to toxin-induced lesion – and/or non-cholinergic retinohypothalamic (RTH) fibers could be necessary to maintain a functional circadian clock.

VIP and Calbidin d28k neurons, for example, are not affected by cholinergic toxin injection in the SCN or intracerebroventricular injection, but since NGF is able to stimulate VIP synthesis and to protect VIP neurons from damage, the possible involvement of Trk-mediated actions is conceivable.

Further, glutamate and gamma-aminobutyric acid transmission have been demonstrated to contribute to the NTs-mediated effects on visual system, and to mediate the light-induced activation of c-fos, extracellular signal-regulated kinase (ERK) 1/2, and clock genes in the SCN.

NTs also affect the response to light by the activation of c-fos, and ERK1/2 in the SCN. These data associated with the evidences that both the TrkA and TrkB receptors are expressed in the SCN, and that the K252a – an inhibitor of the Trk family of NT receptors – blocks light-induced phase shifts when injected in the SCN, further support the functional involvement of Trk receptors in the light-induced response in brain.

It is worth to note that the Trk receptor expression is regulated by NTs, and that in turn, Trks can determine the biological outcome of p75NTR signaling, implying that the variation of local NGF and BDNF levels in SCN might correspond to changes in the receptor-mediated light signal transmission.

To strength this notion, Baeza-Raja et al have recently observed that the expression of NTs and their receptors fluctuates in SCN during the light/dark cycle. Chiefly, these authors show that while the expression of NGF, p75NGFR, and TrkA oscillates in phase with clock genes during the 24 hours, the TrkB levels are unchanged. On the contrary, BDNF shows a different pattern with higher expression levels during the subjective night and the lower ones during the subjective day. The circadian NTs signaling pattern is also observed in the liver, indicating a functional link between the SCN activity and the regulation of peripheral NTs.

Interestingly, the NGF and BDNF levels in the serum and saliva of healthy men and women are also subjected to daily fluctuation, and both the saliva and serum NT levels can be modulated by light. These data further indicate a correspondence between the brain and the peripheral release of NTs, and might support their role as physiological markers of the light-induced rhythmicity.

Similar to what occurs in SCN, a circadian pattern with a night peak of BDNF protein is also observable in the retina, geniculate nucleus, and the visual cortex.
suggested that the low levels of BDNF during the subjective day might be not sufficient to activate the TrkB cascade, and therefore unable to transmit entraining light signals by retina pathways, or in other words, the BDNF secreted at night may be required for light-induced phase shifts.

On the other hand, the NGF trend shows a pick at the subjective day (CT8), and during the night (CT20), and follows the profile of clock genes, indicating a direct relationship between NGF and the SCN activity. In line with this, NGF induces a phase shift of free-running rhythms similar in both direction and circadian phase dependence to light stimuli, when injected at different time points of the circadian time implying that NGF stimulates neuronal pathways, which are coherent with light stimuli.33

The recent evidences that NGF administrated on ocular surface is able to exert effects in the brain might indirectly support this suggestion. Indeed, it has been demonstrated that when ocular administrated in form of eye drops (oNGF), NGF—probably through a trans-conjunctival/trans-scleral route—reaches the retina and the optic nerve and produces effects in the primary visual areas of visual cortex and geniculate nucleus.32

Subsequent studies revealed that oNGF can extend its trophic, differentiative, and regulatory actions on several forebrain structures, and similar to intracerebroventricuлярly injected NGF, oNGF regulates acetylcholine synthesis, induces recovery of damaged brain cholinergic neurons, and stimulates neurogenesis.28,31,32,60

Although different anatomical connections between the eyes and the brain, including those via nasal and nasolacrimal ducts, could mediate the effects of oNGF, the results of studies using radiolabeled NGF and c-fos expression as markers of neuronal activation support the involvement of retinal pathways. Indeed, NGF–I125 is found in the retina and optic nerve when administrated as eye drops indicating the transport through the RGC axons as also previously reported.32,39 The time-dependent activation of primary visual areas has been confirmed by the analysis of c-fos distribution, which also reveals the activation of several limbic areas, including the SCN, the suprachiasmatic nucleus, and the paraventricular hypothalamic nucleus, demonstrating the involvement of the retinohypothalamic pathways.61

In parallel to increased NGF levels and the effect on the Trk and p75NTR expression, oNGF also stimulates the BDNF at both mRNA and protein levels in the retina and results in changes in BDNF in the HIP, septum, and HYP further supporting the central effects of ocular-applied NGF, and a possible cross talk between BDNF and NGF signaling in the retina and retinal recipient brain areas.28,32,66

Although future studies are necessary to better characterize the effects of oNGF on the SCN, and to disclose its potential role in the regulation of the circadian clock, it is possible to speculate that through its direct or indirect actions on other factors known to regulate light response, including BDNF, treatment with oNGF might also be useful in resetting the alteration of circadian rhythms and behaviors in pathological conditions.

**NT-related hypothesis of mood-related disorders**

In the past 30 years, a large amount of data from animal neurobehavioral models, human postmortem studies, brain imaging investigations, and genetic researches have demonstrated the involvement of NTs in depression, NGF and BDNF in particular, and generated the “neurotrophic theory” of affective spectrum disorders.

This theory has initially been based on the assumption that the abnormal neuronal and glial densities and architecture observable in patients with psychiatric disturbances, including depression, might depend on reduced neurotrophic support, and thus on the NGF- and BDNF-mediated protective and reparative actions.62–65

Studies on animal models support this hypothesis demonstrating the correlation between NGF and BDNF expression in brain and depressive behaviors, the response to AD treatments, and the sex-related differences in the vulnerability to depression.66

The study of pathological effects of acute and chronic stress, and environmental changes have also highly contributed to disclose the role of NTs as markers and/or risk factor for mood disorders and generate an integrated model in which the NTs-induced brain plasticity and connectivity rearrangement are directly involved in the brain adaptation and resilience and show that stimuli of psychological nature might be implicated in the mechanisms triggering NGF and BDNF release.23,67

The model of early life stress in animals, including maternal separation, has also been used to demonstrate the role of NTs in the development of anxiety-related behaviors, and therefore to identify NGF and BDNF as biomarkers for emotional and mood disorders associated with events occurring during childhood.24,62,68 Studies on humans contribute to consolidate the “neurotrophic model” by linking neurotrophic factors with the mechanisms of action of drugs used for the
treatment of these disorders and the epigenetic and genetic susceptibility to develop mood disturbances. In particular, patients with major depression show significant lower NGF and BDNF levels in serum, and changes in plasma and serum NGF and BDNF occur after AD treatments among major depressive disorder patients.

Genetically, a functional variant of BDNF at codon 66 (val66met) has been identified with the Met allele that results in abnormal intracellular packaging and secretion of BDNF, and it is associated with poorer episodic memory and reduced hippocampal N-acetyl aspartate. This BDNF val allele is reported to be a possible risk locus for bipolar disorder, but studies in Asian populations have not observed this association. Jiang et al found that met66 variant is a risk allele for anxiety, while a single-nucleotide polymorphism in the BDNF exon 1 promoter that decreases promoter activity, −281 C4A, may be protective against anxiety disorders and major depression.

Like BDNF met66, also, NGF val35 is thought to affect intracellular processing and secretion of the NGF protein, and NGF rs6330 is associated with changes in NGF and NGF receptors in the plasma relatively to the homozgytes CC or CT and TT genotypes, in both psychiatric patients and healthy subjects.

Sex differences in the daily NGF and BDNF levels in serum of healthy subjects and psychiatric patients further support the role of NTs in the regulation of physiological and psychological dimensions of mood.

### Chronopathology and chronopharmacology of mood-related disorders

The first studies on the role of the chronobiological factors in mental diseases were performed in the 1970s. However, just in the past 30 years, research was developed, and more relevant results were in the concept of seasonality and the demonstration of a relationship between circadian patterns and psychiatric disorders. Seasonal fluctuation of mood is observed in patients affected by the main psychiatric disorders, even though it is particularly evident in subjects affected by mood-related disorders. In Diagnostic and Statistical Manual of Mental Disorders, fifth edition, “seasonal pattern” is a specifier applied to the pattern of major depressive episodes or to the presence of at least one type of episode (mania, hypomania, depression) within the diagnosis of recurrent major depressive disorder or bipolar disorder, respectively. Its essential feature is the onset and remission of the various episodes at characteristic times of the year. In most cases, major depressive episodes begin in fall and winter, directly related to day length decreasing, and remit in spring, as day length begins to increase. These episodes are often characterized by prominent energy, hypersomnia, overeating, weight gain, and a craving for carbohydrates. In the study by LeGates et al, a direct association between diminished light exposure and mood functions was demonstrated. What is more, this association was clearly mediated by the ipRGCs. With regard to bipolar disorder, a profound switch in mood between periods of mania and depression has also been reported. As for major depression, in most cases, shifts to the depressive phase have been observed to begin in autumn as day length decreases and often persist throughout the winter. By March, when day length begins to increase, hypomanic/manic episodes become more prevalent, a phenomenon nicknamed “March madness.” At the basis of these two seasonal forms of depression, two major hypotheses have been postulated: altered pineal gland melatonin daily rhythms and circadian phase shift (for a review, see LeGates et al). Apart from seasonal forms of depression, monthly and circadian biological clock impairment have also been described in this disorder. Circadian disturbances of the main physiological functions have widely been reported in patients with nonseasonal depression, including increased mean core temperature and decreased period amplitude. Compared with healthy subjects, patients with depression also show a circadian oscillation in plasma cortisol, norepinephrine, and prolactin, as well as abnormal patterns of melatonin secretion. With regard to depressive symptomatology, the majority of patients have been shown to present a daily pattern of symptoms, usually more severe in the morning. Up to 90% of these patients report an increase in nocturnal activity, which is accompanied by a decrease in sleeping time and the extended exposure to artificial light at night, while only a minority of them (6%–29%) report hypersomnia. Objective sleep measures are also disturbed. A phase-advance pattern of rapid-eye-movement activity and changes in dream experience are frequently observed, and as theorized by Freud, “...we must recognize in the dream, the guardian of sleep…”, a biological function and signal of psychophysical balance in sleep maintenance. Depressed patients also differ in sustained alertness over the 24-hour cycle, specifically with a reduced daytime alertness, compared with normal. Moreover, diurnal patterns of motor activity tend to differ between patients with mood disorders and healthy subjects. Reaction time and cognitive performance are impaired in morning testing but not evening testing.

Of note, circadian disturbances have been demonstrated to affect treatment response and clinical outcome, and this is not...
only in depression. Indeed, many drugs show effects/adverse events that vary over the 24 hours of a day, and these variations represent true circadian rhythms in response (eg, they persist in constant environmental conditions). Besides, drug kinetics that govern disposition of drugs (and even target organ sensitivity) show circadian rhythms, and at least some of them are under the control of molecular clocks.

To date, chronotherapeutics has been shown to be particularly effective in the treatment of allergic rhinitis, arthritis, asthma, cancer, myocardial infarction, peptic ulcer disease, and stroke. In the treatment of depression, the word “chronotherapeutics” has taken on a broader significance referring not only to a treatment scheduling corresponding to a specific patient’s biological clock but also to a controlled exposure to various environmental stimuli and medications acting on biological (circadian) rhythms, in order to achieve targeted therapeutic effects.

A circadian rhythm in the effects/adverse events of a number of mental health medications, including ADs and mood stabilizers, has been demonstrated. These rhythms seem to represent endogenous circadian rhythms resulting from the rhythmicity in drug susceptibility of the brain, which is not dependent on drug kinetics but on rhythms of neurotransmitters, receptors, and second messengers. Back in 1978, the potent norepinephrine uptake blocker lofepramine was shown to present a greater AD effect during a 3-week course of therapy when administered at 12 am than when administered at 8 am or 4 pm. In the study by Nagayama et al, the AD effect of the 5-HT blocker clomipramine during 4 weeks of therapy varied depending on the time of administration. In this case, administration at noon was more effective than administration in the morning or in the evening. It has been observed that the norepinephrine and 5-HT systems in the brain present diverse circadian rhythms, with a peak in the release of these two neurotransmitters during the middle dark period for the former and at noon for the latter. This difference could be at the basis of the 24-hour rhythm change in the efficacy of the two tricyclic ADs, although the literature contains only scattered reports that have failed to confirm a circadian rhythm in the effects/adverse events of the various ADs.

**NGF and BDNF as neuromodulators of chronotherapeutics of depression**

As mentioned earlier, in the treatment of depression, chronotherapeutics also refers to interventions known to modulate the circadian clock. In a microarray study including 12,000 transcripts, Li et al observed widespread changes in cyclic gene expression in six regions of postmortem brain tissue of depressed patients matched with controls. Specifically, they showed an abnormal phasing of circadian gene expression in patients, with the most robust change seen in the anterior cingulate. In fact, interventions able to induce phase shift (generally a phase advance) in circadian rhythms have been demonstrated to have AD effects. These interventions encompass both non-pharmacological and pharmacological strategies. Among the former, sleep deprivation therapy (keeping patients awake for ~36 hours), sleep phase advance (setting sleep time earlier and advancing bedtimes over subsequent nights), and morning bright light therapy (10,000 lux) have been shown to have the most robust AD properties. Their effect is claimed to be rapid but transient, however, with the possibility to be stabilized by combinations of the different chronotherapeutic interventions among themselves and/or with conventional psychiatric treatments (for a review, see Wirz-Justice).

In this regard, adjunctive triple chronotherapy (combined total sleep deprivation, sleep phase advance, and bright light therapy) has recently been demonstrated to induce a rapid improvement in depressive symptoms in drug-resistant mood disorders and acutely suicidal depressed in-patients without early relapse. Remarkably, all these interventions have been shown to directly act on clock gene machinery. Studies of clock gene expression in the mice brain suggest that sleep deprivation can produce rapid (within hours) alterations. Sleep phase advance, morning bright light therapy, and morning “blue” light stimulation have also been reported to affect daily clock gene expression measured in peripheral human blood. Regarding pharmacological strategies, there is evidence that the selective serotonin reuptake inhibitor drug fluoxetine modulates the activity of the circadian biological clock, via phase advance in the firing of SCN neurons, further increasing the expression of various clock genes in the mice brain. Agomelatine, a novel dual melatonergic and specific serotonergic AD, can also cause phase-advance shifts in both mice and hamster brain when administered at specific times of day. Potential actions of agomelatine on clock gene expression have not been reported so far. Using neuronal cell cultures, low doses of the rapid-acting AD ketamine, a noncompetitive N-methyl-D-aspartate receptor antagonist, have been shown to blunt the amplitude of the transcription of different clock genes. More recently, one study has reported the effect of escitalopram on circadian genes in subjects with major depressive disorder. Of note, phase-advance shift of all these non-pharmacological
and pharmacological interventions is contrasted with those of the mood stabilizers lithium and valproate, which can induce a phase delay. However, in clinical studies, both lithium and valproate have their principal effect on mania (and prevention of manic relapse) rather than acute depressive states. Lithium has also been shown to modulate multiple members of clock gene machinery. Noteworthy, glycogen synthase kinase-3β (GSK-3β), a key component of the mammalian circadian clock able to affect circadian rhythm generation by modifying the stability of circadian clock molecules, has been indicated as a common molecular target for many of the aforementioned chronotherapeutic interventions. Sleep deprivation response rates have been reported to be higher in depressed patients who carry a gene promoter polymorphism (rs334558) for decreasing GSK-3β activation. Lithium, valproate, serotonergic ADs, as well as agomelatine and low-dose ketamine increase GSK-3β phosphorylation/inactivation. Through the inhibition of GSK-3β via multiple signaling cascades such as the phosphatidylinositol-3-kinase (PI3K)/Akt and the MAP kinase kinase (MEK)/ERK pathways, all these treatments are hypothesized to regulate the transcription and expression of different neurotrophic, angiogenic, and neuroprotective proteins (for a review, see Chiu et al). Valproate has also been shown to act through the inhibition of histone deacetylase. Both PI3K/Akt and MEK/ERK pathways have, as a downstream target, the cyclic adenosine monophosphate response element transcription factor (CREB). When activated through phosphorylation, CREB modulated the expression of neurotrophic and cell-protective proteins, such as BDNF, NGF, and Bcl-2. Interestingly, BDNF and NGF have been reported to function as both downstream molecules resulting from the inhibition of GSK-3β and upstream signals able to inhibit this molecular pathway. Based on these evidences, it is possible to hypothesize an integrated AD/NTs cascade which might influence the different aspect of mood disorders, including circadian rhythm alteration, as illustrated in Figure 3. Indeed, a plethora of studies have reported significantly lower BDNF and NGF peripheral levels in patients with major depression. Some clinical studies have evaluated the changes in plasma or serum BDNF and NGF levels before and after AD treatments among patients with major depressive disorder, and most studies report increases in the BDNF levels following a course of AD treatment. With regard to NGF, almost all the researches have revealed no statistically significant difference before and after treatment. With regard to pharmacological and non-pharmacological chronotherapeutic interventions,

Figure 3 Schematic illustration of the hypothesis of NGF and BDNF involvement in the mechanism of action of ADs.

Notes: The inhibition of GSK-3 and HDACs is indicated as the two main pathways through which ADs regulate the transcription and expression of factors critically involved in neuroprotective, neurotrophic, anti-inflammatory, neurogenic, and angiogenic functions, thus resulting in the effective treatment of mood disorders. Along with these factors, NGF and BDNF might contemporaneously be regulated by, and induce, GSK-3 inhibition, and/or potentiate the effects of ADs action by activating MEK/ERK pathways. The ADs/neurotrophin signaling cascade is suggested to influence the different aspects of mood disorders, including circadian rhythm alteration, by stimulating neuronal survival and plasticity, inducing neurogenesis, and counteracting the pathological mechanisms, which may trigger and/or aggravate mood alterations, such as brain inflammation and drug abuse.

Abbreviations: ADs, antidepressants; BDNF, brain-derived neurotrophic factor; GDNF, glial cell line-derived neurotrophic factor; GSK-3, glycogen synthase kinase-3; HDACs, histone deacetylases; MEK/ERK, mitogen-activated protein kinase kinase/extracellular signal-regulated kinase; MMP, matrix metalloproteinase; NGF, nerve growth factor; PI3K, phosphatidylinositol-3-kinase; VEGF, vascular endothelial growth factor; VPA, valproate.
escitalopram, ketamine, lithium, and sleep deprivation have all been demonstrated to increase BDNF peripheral levels in patients with major depression.\textsuperscript{141-144} The improvement of depressive symptoms with escitalopram coincided with significant improvements in the recall of both the quantity and quality of dreams, and dreaming, therefore, could be considered a biomarker of the efficacy of AD therapy, also for its evidence of chronobiological trends.\textsuperscript{98,145} Animal models have also confirmed a BDNF change in rat HIP following agomelatine, while treatment with escitalopram affects BDNF expression in HIP and NGF in the cortex but not in other brain areas and serum.\textsuperscript{146,147} In a rat model of depression, Angelucci et al found that treatment with lithium alters the concentrations of NGF and BDNF in the HIP, frontal cortex, occipital cortex, and striatum, further supporting the role of NTs in the mechanism of action of ADs.\textsuperscript{148}

With regard to non-pharmacological chronotherapeutic treatments, sleep deprivation in depressed patients has showed to produce a rapid increase in BDNF levels after a single treatment, and affect diurnal serum profile in responding patients.\textsuperscript{144,149} Light therapy has also showed to affect the diurnal trend of BDNF in the serum and saliva of young healthy women, and serum BDNF concentration in both men and women correlates with the sunshine hours per week throughout the year in both men and women, and with the seasonality of depressive symptoms.\textsuperscript{58,150} No data on the effects of sleep deprivation on the NGF diurnal and/or nocturnal profile in humans are available at present. However, studies in animals demonstrate that selective sleep deprivation during the rapid-eye-movement sleep phase alters the expression of NGF and BDNF in brain of rodents, and that the effects of sleep deprivation on the NGF expression in somatosensory cortex of rats are influenced by the afferents input.\textsuperscript{151,152} Recently, Hight et al found that the expression of NGF in somatosensory cortical neurons is high during the dark phase, while it is low during the light phase.\textsuperscript{153} On the contrary, high levels of NGF are expressed in the visual cortex during the light phase, further supporting the modulation of NGF expression in brain pathways activated by light stimuli, and therefore that changes in circulating or brain NGF and BDNF levels might reflex the light/dark cycle. Remarkably, a daily fluctuation of NGF and BDNF in human serum and plasma, also related to sex, has been found in healthy subjects.\textsuperscript{82} For example, diurnal BDNF rhythm was recently demonstrated in healthy men, where plasma BDNF and cortisol trends display highest concentrations in the morning, followed by a substantial decrease throughout the day, with lowest values at midnight.\textsuperscript{154} In women, the BDNF diurnal variations are also associated to the cortisol rhythm, but they are further influenced by ovarian function and contraceptive therapy.\textsuperscript{155} At variance, Piccinni et al did not find diurnal variation of BDNF in the plasma of women in either the follicular or luteal phase of the menstrual cycle, while variation in plasma BDNF levels was detected in men, with the peak at 8 am and nadir at 10 pm.\textsuperscript{156} BDNF fluctuation in serum and saliva was also found in healthy women.\textsuperscript{58} In agreement with Pluchino et al,\textsuperscript{155} this study shows that both the saliva and the serum BDNF levels in young women in their follicular phase of the ovarian cycle tend to decrease from morning to night and also shows that BDNF trend correlates with morning–evening personality traits and habits, and it is affected by light therapy. These data have recently been reconfirmed by Tirassa and Iannitelli, in a study further exploring the sex difference in the daily trend of NGF and BDNF serum levels (unpublished). Specifically, the study shows that the BDNF levels in men increase from morning to night, while daily NGF presents the “V” shape trend already reported by Bersani et al,\textsuperscript{82} but serum NGF trend in both man and woman is affected by light exposure. While a number of studies are now available on diurnal variation of NTs levels, at present, only one study has investigated this same issue in patients with depression. In the work by Giese et al, diurnal BDNF oscillations in patients with major depression associated with therapeutic response (in both sexes) after partial sleep deprivation.\textsuperscript{144} Specifically, subjects identified as responders (after 2 weeks of treatment) were associated with a daily change in serum BDNF at day 1 and even pretreatment, at baseline. This variation of peripheral BDNF concentration revealed characteristics of a diurnal pattern, whereas nonresponders did not exhibit diurnal BDNF variation. Together, all these findings emphasize the importance of a circadian NT rhythm in human health and well-being, while its absence seems to have a negative impact on successful depression treatment outcome. They further support a direct link between depression, biological clock, chronotherapeutics, and brain plasticity.

**Conclusion**

The data presented support the role of NGF and BDNF in the chronopathology and chronotherapeutics of mood, and therefore suggest these NTs as valuable biomarkers in human studies. Further, the fascinating hypothesis that ocular-applied NTs (by stimulating the retinal pathways associated with NIF functions) might also reset circadian rhythms offers a new interesting field of investigation in neuroscience and psychiatry.
Disclosure

The authors report no conflicts of interest in this work.

References


